Roke has led to clinical trials targeting PMNs to minimize infarct volume, most of which have not been successful [25]. Whilst this may possibly in part be attributable to elements which include patient cohort size or demography, or adverse effects on the PMN targeting strategies [36], the information presented right here suggest that the part of PMNs in ischemic stroke remains unclear and needs a